Akari Therapeutics, Plc (AKTX)
After hours:
Akari Therapeutics, Plc
75/76 Wimpole Street
London W1G 9RT
United Kingdom
44 20 8004 0270
https://www.akaritx.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 9
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Rachelle Suzanne Jacques | President, CEO & Director | 632.25k | N/A | 1971 |
| Ms. Wendy F. DiCicco CPA | Interim Chief Financial Officer | 540.34k | N/A | 1967 |
| Ms. Melissa Bradford-Klug | Chief Operating Officer | N/A | N/A | 1970 |
| Dr. Miles Nunn | Chief Scientific Officer | N/A | N/A | 1969 |
| Dr. John F. Neylan III, M.D. | Executive VP & Chief Medical Officer | N/A | N/A | 1953 |
Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.
Corporate Governance
Akari Therapeutics, Plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
